Johnson & Johnson Proposes $5.5 Billion Settlement to Resolve Ovarian Cancer Talc Lawsuits
The healthcare giant seeks to end thousands of long-running lawsuits over its talc-based baby powder.
Johnson & Johnson has proposed an estimated $5.5 billion settlement to resolve roughly 76,000 lawsuits linking its talc-based products to ovarian cancer, moving to dismantle the vast majority of personal injury litigation that has burdened the healthcare giant for over a decade.
The proposed deal targets claims consolidated in a New Jersey federal court alongside related state court proceedings. To become final, the agreement requires approval from at least 95 percent of eligible ovarian cancer claimants.
Under the structured payout, Johnson & Johnson expects to disburse approximately $3 billion in 2027, with the remainder slated for 2028. However, plaintiff attorneys indicate the total expenditure could rise higher. Chris Seeger, a lead negotiator representing approximately 2,500 claimants, noted that because the agreement sets specific values for qualifying claims without capping the total payout, Johnson & Johnson’s ultimate liability could top $7 billion.
By excluding future claims, the deal concentrates available funds on existing plaintiffs and accelerates disbursements, allowing claims to be settled within an 18-month window rather than stretching over decade-long timelines.
Throughout the legal battle, Johnson & Johnson has maintained that its cosmetic talc was safe, asbestos-free, and did not cause cancer. Erik Haas, the company’s worldwide vice president of litigation, stated that while the firm remained confident it would prevail in court, the resolution allows the business to eliminate legal uncertainty and reallocate resources toward medical technologies and pharmaceuticals.
Talc and asbestos are naturally occurring minerals that often form close to one another in earth deposits, leading to regulatory scrutiny over potential cross-contamination. According to guidance from the U.S. Food and Drug Administration, cosmetic products are not required to undergo pre-market approval, though manufacturers bear legal responsibility for ensuring product safety. Facing widespread consumer concern and thousands of filings, Johnson & Johnson discontinued sales of its talc-based baby powder in the United States and Canada in 2020, replacing it with a cornstarch formulation before expanding the phase-out globally in 2023.
The settlement follows years of complex corporate maneuvers and mixed courtroom results. Johnson & Johnson previously attempted to resolve the liabilities by transferring them into a subsidiary, LTL Management, which filed for Chapter 11 bankruptcy protection—a tactic commonly referred to as a “Texas Two-Step.” Federal appellate courts repeatedly rejected those filings, ruling that the subsidiary was not in financial distress.
Courtroom verdicts had also exposed the company to immense financial volatility, including a 2018 Missouri case where a jury originally awarded $4.69 billion to 22 women, a judgment later reduced on appeal to $2.1 billion. Johnson & Johnson had already negotiated separate settlements covering most claims alleging its talc contained asbestos that caused mesothelioma.
The momentum toward a comprehensive agreement built after recent defense victories in court, including rulings striking down plaintiff expert witnesses and a decision by a federal judge questioning whether individual plaintiffs could scientifically establish that talc caused their specific cancer cases.
